<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-77589</identifier>
<setSpec>0214-3429</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">In vitro generation of mutants of Klebsiella pneumoniae following exposure to fluorquinolones. Relationship with the presence of extended spectrum betalactamases</dc:title>
<dc:description xml:lang="en">In order to provide data that may help to explain therelationship between production of extended spectrumbetalactamases and fluorquinolone resistance in Klebsie-lla pneumoniae, we have developed an in vitro model ofexposure to sub-inhibitory concentrations of variousfluorquinolones (ciprofloxacin, levofloxacin and moxifloxacin)in two strains, one of which is a producer ofextended spectrum betalactamases (ESBL).Our data show that mutants with reduced fluorquinolonesusceptibility appear in both cases, but that theyappear earlier in ESBL-producing strains (13.3 days versus14.4 days), especially following exposure to ciprofloxacin(12.5 days versus 14.9 days for levofloxacin and14.2 days for moxifloxacin).Therefore, our data help explain the greater fluorquinoloneresistance in ESBL-producing strains and confirmthe need to administer the correct doses of fluoroquinolones,especially in the case of ciprofloxacin, in order toprevent the emergence of resistant mutants. This is particularlyimportant if the strain is an ESBL-producer (AU)</dc:description>
<dc:creator>Ruiz, M</dc:creator>
<dc:creator>Rodríguez, J. C</dc:creator>
<dc:creator>Cremades, R</dc:creator>
<dc:creator>Royo, G</dc:creator>
<dc:creator>Noguera, O</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Con objeto de aportar datos que ayuden a explicar laasociación entre producción de betalactamasas de espectroextendido (BLEE) y resistencia a fluoroquinolonas en Klebsiellapneumoniae, hemos desarrollado un modelo in vitro deexposición a concentraciones subinhibitorias de varios fármacosde esta familia (ciprofloxacino, levofloxacino y moxifloxacino)con dos cepas, una productora de BLEE.Nuestros datos muestran que aparecen mutantes consensibilidad disminuida a fluoroquinolonas en los dos casos,pero más precozmente en cepas productoras de BLEE (13,3frente a 14,4 días), sobre todo tras exposición a ciprofloxacino(12,5 frente a 14,9 días para levofloxacino y 14,2 díaspara moxifloxacino).Por tanto, nuestros datos ayudan a explicar la mayorresistencia a fluoroquinolonas en cepas productoras de BLEEy confirman la necesidad de administrar dosis adecuadas defluoroquinolonas, especialmente de ciprofloxacino, con objetode prevenir la aparición de mutantes resistentes, sobretodo si la cepa es productora de BLEE (AU)</dc:description>
<dc:source>Rev Esp Quimioter;21(3): 180-183, sep. 2008. tab</dc:source>
<dc:identifier>ibc-77589</dc:identifier>
<dc:title xml:lang="es">Generación in vitro de mutantes de Klebsiella pneumoniae tras exposición a fluoroquinolonas. Relación con la presencia de betalactamasas de espectro extendido</dc:title>
<dc:subject>^d4835^s22031</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d4835^s22021</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d36060^s22079</dc:subject>
<dc:subject>^d4835^s22038</dc:subject>
<dc:subject>^d36060^s22065</dc:subject>
<dc:subject>^d7887^s22038</dc:subject>
<dc:subject>^d36060^s22000</dc:subject>
<dc:subject>^d7887^s22021</dc:subject>
<dc:subject>^d28455^s22066</dc:subject>
<dc:subject>^d36060^s22073</dc:subject>
<dc:subject>^d32344^s22021</dc:subject>
<dc:subject>^d7887^s22052</dc:subject>
<dc:type>article</dc:type>
<dc:date>200809</dc:date>
</metadata>
</record>
</ibecs-document>
